Cargando…
Progesterone supplementation for HIV-positive pregnant women on protease inhibitor-based antiretroviral regimens (the ProSPAR study): a study protocol for a pilot randomized controlled trial
BACKGROUND: In Canada, the majority of HIV-positive pregnant women receive combination antiretroviral therapy that includes a ritonavir-boosted protease inhibitor to prevent mother-to-child HIV transmission. However, protease inhibitor-based combination antiretroviral therapy has been associated wit...
Autores principales: | Siou, Kaitlin, Walmsley, Sharon L., Murphy, Kellie E., Raboud, Janet, Loutfy, Mona, Yudin, Mark H., Silverman, Michael, Ladhani, Noor N., Serghides, Lena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153916/ https://www.ncbi.nlm.nih.gov/pubmed/27965866 http://dx.doi.org/10.1186/s40814-016-0087-6 |
Ejemplares similares
-
Erratum to: Progesterone supplementation for HIV-positive pregnant women on protease inhibitor-based antiretroviral regimens (the ProSPAR study): a study protocol for a pilot randomized controlled trial
por: Siou, Kaitlin, et al.
Publicado: (2017) -
HIV Protease Inhibitor Use During Pregnancy Is Associated With Decreased Progesterone Levels, Suggesting a Potential Mechanism Contributing to Fetal Growth Restriction
por: Papp, Eszter, et al.
Publicado: (2015) -
Perinatal outcomes in women living with HIV‐1 and receiving antiretroviral therapy—a systematic review and meta‐analysis
por: Shinar, Shiri, et al.
Publicado: (2021) -
In utero exposure to protease inhibitor-based antiretroviral regimens delays growth and developmental milestones in mice
por: Sarkar, Ambalika, et al.
Publicado: (2020) -
Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
por: Antoniou, Tony, et al.
Publicado: (2017)